|Bid||8.70 x 3000|
|Ask||9.05 x 4000|
|Day's range||8.63 - 8.76|
|52-week range||6.78 - 11.34|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||9.70|
Here is your weekly roundup of the biggest news out of hedge funds and company top brass, all first covered on InvestingPro+.
Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.
TEL AVIV, Israel & PARSIPPANY, N.J., November 22, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the company has finalized the documentation of its proposed nationwide opioid settlement with both the working group of States’ Attorneys General and the Multi-District Litigation Plaintiffs’ Executive Committee. Allergan has also finalized its settlement terms. As announced during the Company’s third quarter earnings ca